Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7002420 | PMC |
| http://dx.doi.org/10.1038/s41433-019-0418-y | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cardiac findings in a phase II double-blind randomized placebo-controlled trial of combination therapy (HAZDPac) to treat COVID-19 patients.
BMC Cardiovasc Disord
December 2024
Community Memorial Hospital, Ventura, CA, USA.
Objective: Hydroxychloroquine paired with Azithromycin, Vitamin C, Vitamin D, and Zinc (HAZDPac), was used as a multidrug therapy method to treat COVID-19 illness and superimposed secondary bacterial pneumonia. Concerns have been raised though about such combinations regarding cardiac QTc interval prolongation and risks of arrhythmias, which we set out to address in this study.
Design: We evaluated cardiac safety in a Phase II Double-Blind Randomized Placebo-Controlled Trial of Combination Therapy to Treat COVID-19 Infections study, conducted by ProgenaBiome.
Efficacy of combining aspirin with hydroxychloroquine in pregnancies at high risk for pre-eclampsia: a prospective, multicentre, open-label, single-arm clinical trial, investigator-initiated study (HUGS study).
BMJ Open
December 2024
Department of Obstetrics and Gynecology, Samsung Medical Center, Seoul, Korea (the Republic of).
Introduction: The use of hydroxychloroquine (HCQ) during pregnancies complicated by systemic lupus erythematosus or refractory antiphospholipid antibody syndrome has demonstrated a significant ability to prevent pre-eclampsia (PE). As such, the potential for the administration of HCQ to prevent PE in other high-risk pregnancies is an important clinical research agenda among maternal and fetal medicine specialists. Mechanistically, the anti-inflammatory and immunomodulatory effects of HCQ can offer vascular protection and inhibit the placental dysfunction-associated thrombotic changes underlying the pathophysiology of PE, fetal growth restriction (FGR) and fetal death in utero (FDIU).
View Article and Find Full Text PDFCyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study.
Microbiol Spectr
November 2024
Fujian Institute of Clinical Immunology, Fujian Medical University Union Hospital, Fuzhou, China.
Article Synopsis
- The study investigates how cyclosporine (CsA) affects COVID-19 infection in systemic lupus erythematosus (SLE) patients, aiming to give insights for clinical treatment amid ongoing COVID-19 risks.
- It included 184 SLE patients and split them into two groups: one using CsA and the other relying on glucocorticoids or hydroxychloroquine.
- Results showed that CsA was linked to lower chances of symptomatic COVID-19, suggesting it could be a beneficial treatment option for SLE patients dealing with severe disease and persistent SARS-CoV-2 infection.
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
Ann Rheum Dis
September 2024
Academic Department of Rheumatology, Kings College London, London, UK
Multiple clinical trials for rheumatoid arthritis (RA) prevention have been completed. Here, we set out to report on the lessons learnt from these studies. Researchers who conducted RA prevention trials shared the background, rationale, approach and outcomes and evaluated the lessons learnt to inform the next generation of RA prevention trials.
View Article and Find Full Text PDFOculometric biomarkers of visuomotor deficits in clinically asymptomatic patients with systemic lupus erythematosus undergoing long-term hydroxychloroquine treatment.
Front Ophthalmol (Lausanne)
July 2024
Human Systems Integration Division, Ames Research Center, National Aeronautics and Space Administration, Moffett Field, CA, United States.
Introduction: This study examines a set of oculomotor measurements, or "oculometric" biomarkers, as potential early indicators of visual and visuomotor deficits due to retinal toxicity in asymptomatic Systemic Lupus Erythematosus (SLE) patients on long-term hydroxychloroquine (HCQ) treatment. The aim is to identify subclinical functional impairments that are otherwise undetectable by standard clinical tests and to link them to structural retinal changes.
Methods: We measured oculomotor responses in a cohort of SLE patients on chronic HCQ therapy using a previously established behavioral task and analysis technique.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!